Carya Illinoinensis

Funapide (INN) (former developmental code names TV-45070 and XEN402) is a novel analgesic under development by Xenon Pharmaceuticals (formerly in partnership with Teva Pharmaceutical Industries) for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain.^[1]^[2]^[3]^[4] It acts as a small-molecule Na_v1.7 and Na_v1.8 voltage-gated sodium channel blocker.^[1]^[2]^[4] Funapide is being evaluated in humans in both oral and topical formulations, and as of July 2014, has reached phase IIb clinical trials.^[1]^[3]

References

^ ^a ^b ^c Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
^ ^a ^b Ali Z, Palmer JE, Goli V (2013). "Anticonvulsants: Clinical". In McMahon S, Koltzenburg M, Tracey I, Turk DC (eds.). Wall & Melzack's Textbook of Pain (6 ed.). Elsevier Health Sciences. p. 508. ISBN 978-0-7020-4059-7. OCLC 1008841684.
^ ^a ^b "TV-45070: A Small Molecule for the Treatment of the Orphan Disease EM and Other Pain Disorders". Xenon Pharma. Archived from the original on 15 July 2013.
^ ^a ^b "Teva and Xenon Announce Teva's World Wide License of Xenon's Pain Drug XEN402". Xenon Pharma. 11 December 2012. Archived from the original on 26 July 2014. Retrieved 2014-07-20.

"Funapide - Flexion Therapeutics". AdisInsight. Springer Nature Switzerland AG.